Interaction Between Olanzapine and Pregabalin for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting—A Randomized Factorial Clinical Trial With Simulation

Purpose In low- and middle-income settings where NK1 receptor antagonists are often unaffordable, we evaluated the interaction and efficacy of add-on olanzapine plus pregabalin for chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Methods In this single-center 2 × 2 factorial, double-blind, add-on placebo-controlled trial, 104 participants receiving HEC were randomly assigned 1:1:1:1 to olanzapine 5 mg, pregabalin 75 mg, their combination, or placebo once daily for 4 days, with standard ondansetron and dexamethasone. The primary outcome was the olanzapine × pregabalin interaction on the mean 5-day Visual Analog Scale (VAS) nausea score. Secondary outcomes included no nausea, no significant nausea (VAS < 2.5), no vomiting, complete response/control, Functional Living Index–Emesis, and adverse events. Clinical-trial simulation explored the interaction at larger n and identified minimum effective doses. Results No significant olanzapine × pregabalin interaction was detected on mean VAS (coefficient, 0.44 [95% CI, –0.89 to 1.77]; P = .52); effects were consistent with additivity at the trial sample size. Simulation at n ≥ 600 suggested a small antagonistic term, interpreted as hypothesis-generating. The combination arm had the lowest overall 5-day VAS (0.89, standard deviation [SD], 1.07) versus placebo (3.68, SD 2.06; analysis of variance P < .001); secondary outcomes favored the combination and are reported as hypothesis-generating. Emax modeling supports a future dose-reduced regimen of olanzapine 5 mg + pregabalin 50 mg once daily or olanzapine 2.5 mg + pregabalin 75 mg once daily to preserve efficacy while reducing toxicity. Sedation and dizziness were more frequent in the study-drug arms. Conclusion In patients receiving HEC, add-on olanzapine 5 mg + pregabalin 75 mg once daily improved nausea control versus placebo, with effects consistent with additivity. No synergy was demonstrated; the simulation-based antagonism signal warrants confirmation, and a dose-reduced combination is proposed for future evaluation.

Authors

Institutions

Publication Details

Journal
JCO Oncology Practice
Published
2026-11-19
DOI
https://doi.org/10.1200/op-25-00315
Primary Topic
Nausea and vomiting management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Interaction Between Olanzapine and Pregabalin for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting—A Randomized Factorial Clinical Trial With Simulation

Dillip Kumar Parida, Milan Padhan, Archana Mishra, Debasish Hota et al.
JCO Oncology Practice
Nausea and vomiting management
article

Interaction Between Olanzapine and Pregabalin for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting—A Randomized Factorial Clinical Trial With Simulation

Dillip Kumar Parida, Milan Padhan, Archana Mishra, Debasish Hota, Mathan Kumar Ramasubbu, Rituparna Maiti, Anand Srinivasan, Saroj Kumar Das Majumdar, Priyanka Mukherjee
article en

Abstract

Purpose In low- and middle-income settings where NK1 receptor antagonists are often unaffordable, we evaluated the interaction and efficacy of add-on olanzapine plus pregabalin for chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Methods In this single-center 2 × 2 factorial, double-blind, add-on placebo-controlled trial, 104 participants receiving HEC were randomly assigned 1:1:1:1 to olanzapine 5 mg, pregabalin 75 mg, their combination, or placebo once daily for 4 days, with standard ondansetron and dexamethasone. The primary outcome was the olanzapine × pregabalin interaction on the mean 5-day Visual Analog Scale (VAS) nausea score. Secondary outcomes included no nausea, no significant nausea (VAS < 2.5), no vomiting, complete response/control, Functional Living Index–Emesis, and adverse events. Clinical-trial simulation explored the interaction at larger n and identified minimum effective doses. Results No significant olanzapine × pregabalin interaction was detected on mean VAS (coefficient, 0.44 [95% CI, –0.89 to 1.77]; P = .52); effects were consistent with additivity at the trial sample size. Simulation at n ≥ 600 suggested a small antagonistic term, interpreted as hypothesis-generating. The combination arm had the lowest overall 5-day VAS (0.89, standard deviation [SD], 1.07) versus placebo (3.68, SD 2.06; analysis of variance P < .001); secondary outcomes favored the combination and are reported as hypothesis-generating. Emax modeling supports a future dose-reduced regimen of olanzapine 5 mg + pregabalin 50 mg once daily or olanzapine 2.5 mg + pregabalin 75 mg once daily to preserve efficacy while reducing toxicity. Sedation and dizziness were more frequent in the study-drug arms. Conclusion In patients receiving HEC, add-on olanzapine 5 mg + pregabalin 75 mg once daily improved nausea control versus placebo, with effects consistent with additivity. No synergy was demonstrated; the simulation-based antagonism signal warrants confirmation, and a dose-reduced combination is proposed for future evaluation.

JCO Oncology Practice
All India Institute of Medical Sciences Bhubaneswar (IN), All India Institute of Medical Sciences (IN)
Nausea and vomiting management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon